title: Endothelin-1-mediated inflammation in acute renal failure.
abstract: Acute renal failure presents a serious and life-threatening problem in hospitalized patients. Current therapies address the systemic alterations in renal failure. Cellular changes also occur. These changes affect the glomerular filtration rate and the integrity of the glomerular membrane. ET-1, the most potent vasoconstrictor known, has a negative effect on both the rate of filtration and the integrity of the filtering membrane in renal failure. Using ET-1 antagonists along with the current therapies may prove useful in patients.
authors.affiliation: School of Nursing and Health Studies, Georgetown University, Washington, DC, USA. angerioa@georgetown.edu
authors.forename: Allan D
authors.initials: AD
authors.lastname: Angerio
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000276:immunology*; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D007249:Inflammation; D007375:Interleukin-1 / Q000276:immunology; D010456:Peptides, Cyclic / Q000627:therapeutic use; D012079:Renal Circulation / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014661:Vasoconstriction / Q000502:physiology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007375:Interleukin-1; D010456:Peptides, Cyclic; D014409:Tumor Necrosis Factor-alpha; C088196:TAK 044; C072247:cyclo(Trp-Asp-Pro-Val-Leu)